JPRN-UMIN000035004已完成1 期
Phase I/IIa investigator-initiated multicenter single-arm open-label study of the safety and efficacy of intravenous HUCV002-01 in patients with chronic heart failure - Phase I/IIa single-arm open-label study of intravenous HUCV002-01 in patients with chronic heart failure
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Those who has any of the following at the time of enrollment should be excluded. 1)Chronic heart failure dues to operable valvular disease or congenital cardiac disease 2)Awaiting cardiac transplant 3)Acute myocardial infarction within 28 days prior to the enrollment 4)Cerebrovascular disease within 28 days before the enrollment 5)Coronary artery revascularization (CAVG, PCI) was performed or planned within 3 months before getting consent or during the clinical study 6)New treatments for cardiac failure was started within 3 months before the enrollment 7)Patients with malignancy or history of malignant diseases within 1 year prior to the study (Except for those who had cured carcinoma in situ or intramucosal carcinoma) 8)Uncontrolled hypertension (systemic BP>160mmHg or diastolic BP>100mmHg) 9)Symptomatic hypotension 10)Autoimmune disease 11)Any of the following within 7 days before the registration a)Hepatic dysfunction: AST > 90 U/L or ALT (male) > 126 U/L, (female) >69 U/L b)Renal dysfunction: eGFR < 15 mL/min/1.73m2 c)Platelet counts < 100 x 10^3/uL d)Hb < 9.0 g/dL 12)Positive for any of HBV, HCV, HIV, HTLV1 or syphilis within 56 days before the enrollment 13)Those who has history or viral hepatitis 14)Patients with uncontrolled active infection 15)Allergic to streptomycin or gentamicin 16)Allergic to animals (pig, sheep, cow) or cows milk 17)Patient who needs systemic steroid or immunosuppressive drugs 18)BSA > 2.0 m2 (Du Bois) 19)Functional gait disorder 20)Pregnant, lactating, or possible pregnant female. Female who wants to become pregnant or male who wants his partner to become pregnant. Those who refuses contraception during the study. 21)Those who participated in other clinical studies within 28 days prior to getting the informed consent. Those who plans to participate in other clinical studies during this study. 22)Patients whom the PI or investigators decided as inappropriate for the study.
研究者
相似试验
招募中
2 期
Phase IIb investigator-initiated multicenter study of the efficacy and safety of intravenous HUCV002-01 in patients with chronic heart failure (continuous study)chronic heart failureJPRN-jRCT2073220002Tsutsui Hiroyuki15
已完成
不适用
An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphomaCohort 1: Subjects with CD30+ mycosis fungoides or pcALCL Cohort 2: Subjects with other (non-Cohort 1) CD30+ cutaneous T-Cell lymphomasJPRN-UMIN000034205Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences15
已完成
2 期
A multicenter, investigator-initiated phase II clinical trial involving administration of a cross-linked gelatin hydrogel containing recombinant human basic fibroblast growth factor (rh-bFGF) to prevent the collapse of the femoral headOsteonecrosis of the femoral headJPRN-UMIN000020340Haruhiko Akiyama, Gifu University Hospital64
招募中
2 期
Phase II Trial to Evaluate the Efficacy and Safety of Combination Therapy with Immune Checkpoint Inhibitors and Photodynamic TherapyJPRN-jRCT2051220176Muto Manabu80
已完成
2 期
Phase II clinical trial of combination therapy with GEN0101 and standard chemotherapy in pleural mesothelioma patients.Malignant Pleural MesotheliomaJPRN-jRCT2080224548ational Hospital Organization Osaka Toneyama Medical Center, Director of a hospital, Meinoshin Okumura50